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Abstract
Background: Osteoarthritis (OA) is a major clinical and public health problem, with no current medications
approved as having disease modifying effects. HMG-CoA reductase inhibitors, or “statins”, a drug class widely
used to prevent cardiovascular events, could potentially affect OA progression via a number of mechanisms
including their effects on lipid metabolism and inflammation. The aim of this multicentre, randomised, double-blind,
placebo-controlled trial is to determine whether atorvastatin reduces the progression of knee structural changes and
symptoms over 2 years in patients with symptomatic knee OA.
Methods/design: 350 patients with symptomatic knee OA will be recruited through the OA Clinical Trial Network
(in Melbourne, Hobart and Adelaide). They will be randomly allocated to the two arms of the study, receiving either
40 mg of atorvastatin or identical placebo once daily for 2 years. Magnetic resonance imaging of the knee will be
performed at baseline and 2 years later. Knee structure, symptoms and function will be assessed using validated
methods. The primary outcome is annual percentage change in knee cartilage volume. Secondary outcomes include
progression of cartilage defects, bone marrow lesions, knee pain and function. The primary analysis will be by intention
to treat, but per protocol analyses will also be performed.
Discussion: The study will provide high-quality evidence to address whether atorvastatin has a novel disease
modifying effect in OA by delaying the structural and symptomatic progression of knee OA. Thus, the trial has major
public health and clinical importance, as if found to be beneficial, atorvastatin could produce substantial cost savings
by delaying and possibly reducing the need for joint replacement surgery, and provide marked improvements in
quality of life for people with OA.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000190707, registered on 18 February
2013.
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Background
Osteoarthritis (OA), characterised by progressive struc-
tural deterioration and symptoms, is a significant clinical
and public health problem, causing pain, disability and a
substantial health care burden. It is a major contributor
to the burden of disease, being ranked as the eleventh
highest contributor of global disability among 291 condi-
tions in the Global Burden of Disease study and associ-
ated with 71.1 million years lived with disability, an
increase of 64 % from 1990 to 2010 [1]. Symptomatic
knee OA makes a significant impact on society, with
44.7 % of people developing this condition in their life-
time [2]. Current treatments for OA mainly focus on the
improvement of symptoms. Although several drugs and
nutraceuticals have been examined for their effects on
slowing structural progression of OA over the past 10 years,
none has been approved as a disease modifying OA drug
[3]. Many patients with symptomatic end-stage OA are
eventually faced with joint replacement as the only treat-
ment option to improve quality of life, and the number of
joint replacements has continued to increase worldwide.
There is growing evidence that OA is a multifactorial
complex disorder, with a significant metabolic compo-
nent in its pathogenesis, in which various interrelated
lipid, metabolic and inflammatory mediators contribute
to the initiation and progression of the disease [4–6].
These metabolic factors appear to be more important in
OA of the knee than the hip [7].
In the Chingford study of 1,003 middle-aged women,
hypercholesterolaemia was associated with increased risk
of knee OA independent of obesity, and the association
was stronger for bilateral knee OA than for unilateral
knee OA [8]. In the Ulm study of 809 patients with joint
replacement due to OA, high serum cholesterol levels
were independently associated with increased risk of
knee OA [9]. In recent longitudinal magnetic resonance
imaging (MRI) studies, we showed that higher serum
cholesterol and triglyceride levels were associated with
adverse structural changes (increased incidence of bone
marrow lesions, BMLs) in asymptomatic middle-aged
women over 2 years [10], while higher serum levels of
high-density lipoprotein (HDL) cholesterol were protect-
ive against worsening of BMLs in older adults over
2.7 years [11]. BMLs are early knee structural changes
associated with knee pain and cartilage loss [12, 13] and
joint replacement in OA [14].
Inflammation has also been implicated in the pathogen-
esis of OA [6]. In human OA, the histological changes
include increased vascularity, lining layer thickening, and
inflammatory cell infiltration with increased numbers of
lining cells. A mixed population of inflammatory cells
(macrophages, activated T cells) is seen in the sublining
tissue [15]. These cells, as well as chondrocytes, produce
pro-inflammatory cytokines, such as interleukin (IL)-1β,
IL-6, and tumour necrosis factor (TNF)-α [15], which are
detectable even in early OA [15]. Synovitis identified by
arthroscopy predicted increased cartilage loss over 1 year
[16], and synovitis detected by contrast-enhanced MRI
was associated with increased cartilage loss over
30 months [17]. Circulating levels of C-reactive protein
were associated with disease progression and decreased
cartilage volume at the knee [18, 19]. Increased serum
level of IL-6 was a significant predictor of radiographic
OA 5–10 years later in women [20], associated with
increased knee cartilage loss over 2 years in OA [21] and
increased cartilage volume loss over 3 years in older adults
[22]. We found that elevated TNF-α levels were also asso-
ciated with increased rate of cartilage volume loss over
3 years in older adults [22].
Hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors (statins), a drug class used to lower
low-density lipoprotein (LDL) cholesterol levels with
smaller effects on lowering triglycerides and increasing
HDL cholesterol levels, are proven and have been widely
used to prevent cardiovascular events [23]. In addition
to lowering LDL cholesterol, statins have a broad range
of pleiotropic effects, including anti-inflammatory ef-
fects, which could exert an effect on synovium and
cartilage [24]. Data from observational studies of statins
are somewhat conflicting (Table 1). Some large cohort
studies have shown that statin use is associated with
reduced incidence and progression of OA [25, 26] and
that higher statin dose and larger statin increments are
associated with reduced incident episode of clinically
defined OA [27]. However, other cohort studies have
reported that statin use is associated with an increased
incidence of OA and arthropathy [28, 29], or that statin
use is not associated with improvement in knee pain,
function, or structural progression of knee OA [30].
Thus, the current evidence for the association between
statin use and the risk of OA comes from observational
human studies which are subject to bias and confounding,
and the overall data are inconclusive. No randomised con-
trolled trials of statins have been performed so far.
We will conduct a randomised controlled trial to de-
termine whether atorvastatin has a disease modifying
effect in OA by reducing the MRI-assessed structural
progression (knee cartilage volume loss, progression of
cartilage defects and BMLs) and symptoms in patients
with symptomatic knee OA over 2 years. It was hypothe-
sised that atorvastatin use will reduce the rate of knee
cartilage volume loss (primary hypothesis), the progres-
sion of cartilage defects and BMLs (secondary hypoth-
esis), and improve symptoms and function (secondary
hypothesis) over 2 years compared with placebo in
people with symptomatic knee OA. If statins are proven
to be effective, they will offer a novel therapeutic ap-
proach to reducing the progression of knee OA.
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Methods/design
Study design
The Osteoarthritis of the Knee Statin (OAKS) study is a
multicentre, randomised, double-blind, placebo-controlled
trial over 2 years. The trial was registered at the Australian
New Zealand Clinical Trials Registry prior to recruitment,
and trial reporting will be guided by the CONSORT
Statement [31]. A total of 350 patients with symptomatic
knee OA will be recruited in equal numbers via the
OA Clinical Trial Network in Melbourne, Hobart and
Adelaide, using a combined strategy including collabor-
ation with general practitioners, rheumatologists, and
orthopaedic surgeons, as well as advertising through
local media. Ethics approval has been obtained from
The Alfred Hospital Ethics Committee (521/12), Monash
University Human Research Ethics Committee (CF13/595
- 2013000236), Tasmania Health and Medical Human
Research Ethics Committee (H0012971), and Human
Research Ethics Committee (TQEH/LMH/MH) (HREC/
13/TQEHLMH/20). Written informed consent will be ob-
tained from all participants.
Inclusion criteria
The inclusion criteria will be: males and females with
symptomatic knee OA for at least 6 months with a
pain score of at least 20 mm on a 100-mm visual
analogue scale (VAS); age 40–70 years old; and meet-
ing the American College of Rheumatology (ACR)
criteria for symptomatic knee OA [32], assessed by a
rheumatologist.
Exclusion criteria
Participants with any of the following conditions will be
excluded: inability to give informed consent; severe
radiographic knee OA (grade 3 according to Altman’s
atlas [33]) or severe knee pain (on standing >80 mm on
a 100-mm VAS); rheumatoid arthritis or other inflam-
matory arthritis; significant knee injury; familial hyper-
cholesterolaemia for which statins are indicated, known
atherosclerotic cardiovascular disease, diabetes mellitus,
taking current lipid lowering therapy, or with previous
adverse reaction to statins; absolute cardiovascular risk
estimated using the Framingham Risk Equation of more
than 15 % within the next 5 years (National Heart
Foundation of Australia, 2005); fasting total cholesterol
level >7.5 mmol/L; clinically significant renal disease or
abnormal liver function assessed by aspartate amino-
transferase and alanine aminotransferase, creatine kin-
ase more than twice the upper limit of laboratory
normal range; patients undergoing arthroscopy or open
surgery in the index knee in the last 12 months; receiving
intra-articular therapy in the index knee in the last
12 months; concomitant use of potent analgesics includ-
ing opiates; co-morbidity that may limit participation
(such as planned index knee joint replacement or medical
conditions, for example, malignancy in the past 5 years
other than non-melanoma skin cancer); relocation; any
Table 1 Summary of findings from human epidemiological studies for association between statin use and risk of osteoarthritis
Author, year Study design Participants Outcome measure Main results




5,674 elderly women aged
≥65 years from the Study of
Osteoporotic Fractures
Radiographic hip OA Statin use was associated with
an increased risk of developing
radiographic hip OA, but did not
adversely affect the progression
of established disease.







databases of a large health
organisation
International Classification of
Diseases, 9th revision, diagnosis
codes
Persistent statin use was associated
with a reduced incidence of OA.
Clockaerts S,




2,921 participants aged ≥55
years in the Rotterdam study
Radiographic knee and hip OA Statin use was associated with
reduced incidence and progression
of radiographic knee OA, but not
radiographic hip OA over 6.5 years.




16,609 adults aged ≥40 years
from the UK General Practice
Research Database
Clinically defined OA: OA-related
diagnostic categories from a
standard clinical classification,
recorded by GPs in the actual
consultations
Higher statin dose and larger statin
increments were associated with
reduced incident episode of clinically
defined OA over 2–10 years.




92,360 patients in the San Antonio
Military Multi-Service Market
International Classification of
Diseases, 9th edition, diagnosis
codes
Statin use was associated with an
increased incidence of OA and
arthropathy over 4 years.






or confirmed knee OA in the
Osteoarthritis Initiative
Knee pain, function, and
radiographic knee OA
Statin use was not associated with
improvement in knee pain, function,
or structural progression of knee OA
over 4 years.
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contraindication to MRI scanning (for example, implanted
pacemaker, metal sutures, presence of shrapnel or iron fil-
ings in the eye, or claustrophobia); pregnancy, breast feed-
ing, or women trying to become pregnant.
Randomisation and blinding
Allocation of participants in a 1:1 ratio to either the inter-
vention or control group will be based on computer-
generated random numbers prepared by a statistician with
no involvement in the trial. Block randomisation will be
performed using a central automated allocation proced-
ure, stratified according to the study site. The randomised
controlled trial will be a double-blind one, with both
participants and investigators assessing outcomes blinded
to treatment allocation. Allocation concealment and
double blinding will be ensured by 1) the medications
being dispensed by the hospital clinical trial pharmacy in
each site; 2) the use of an identical placebo tablet; 3) ob-
jective measures of knee structural changes being made by
trained observers blinded to group allocation and the time
sequence of MRI scans; 4) subjective measures being
taken by research assistants blinded to group allocation.
Intervention
All participants will be provided usual care by their
treating health practitioners. Participants in the inter-
vention arm will receive 40 mg of atorvastatin (Sandoz)
once daily, and those in the control arm will receive
40 mg of inactive matching placebo (Pharmaceutical
Packaging Professionals Pty Ltd, Thebarton, South
Australia) once daily. Atorvastatin was chosen as it is
the most widely prescribed statin and has potent LDL
cholesterol lowering effects.
Study procedure
At screening, participants will complete questionnaires,
have a knee X-ray, and undergo biochemical testing in-
cluding liver function tests, creatine kinase and renal
function tests, to ensure inclusion criteria are met. The
study knee will be defined as the one with symptomatic
OA; if both are symptomatic, the one with least severe
radiographic OA (joint space narrowing) will be studied,
to reduce loss to follow-up for joint replacement. After
screening, study visits will be scheduled for 0 (baseline),
6, 12 and 24 months (Table 2). The same researchers,
who are blinded to treatment allocation, will measure all
clinical variables, administer questionnaires, monitor
compliance, and record adverse events at these visits.
Compliance by trial medication will be assessed by pill
count. Biochemical testing will be performed at 4 weeks,
and at 6, 12 and 24 months. At baseline and 24 months
the index knee will be imaged on the same whole-body
MRI unit.
Quality assurance
To ensure high-quality execution of the trial in accord-
ance with the protocol, all trial staff will be trained by the
chief investigators and provided a standard protocol book
(with details of standard operating procedures used for all
Table 2 Timetable and measures to be made
Screening Month 0 (baseline) Week 4 Month 6 Month 12 Month 18 Month 24
X-ray √
Biochemical testing √ √ √ √ √
Questionnaires √ √ √ √ √
Knee VAS √ √ √ √ √
Knee WOMAC √ √ √ √
IPAQ √ √
SF-36 √ √
Concomitant medications √ √ √ √ √
Smoking √ √
History of joint disease √ √ √
Co-morbidities √ √ √
Education and occupation √
Physical examination √ √
Height and weight √ √
Lower limb muscle strength √ √ √
Knee MRI √ √
Compliance and adverse events √ √ √ √
Medication dispensing √ √ √ √
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Knee MRI acquisition at the three study sites is presented
in Table 3, including details of sequences and parameters
being used.
Primary outcome measure: annual percentage change in
tibial cartilage volume
From sagittal T1-weighted images, medial and lateral tibial
cartilage volume will be isolated by manually drawing dis-
articulation contours around the cartilage boundaries on a
section-by-section basis. Measurement error and bias will
be reduced by ensuring that one reader measures partici-
pants’ paired set of images blinded to time sequence, with
a second reader performing independent consistency
checks. In our previous study, we demonstrated a coeffi-
cient of variation of 2.0–3.4 % for this method [34]. We
and others have shown that change in tibial cartilage vol-
ume over 2 years can be measured using this method and
is both statistically and clinically significant in patients
with symptomatic knee OA [34–36]. The annual percent-
age change in tibial cartilage volume will be calculated as
(follow-up cartilage volume – baseline cartilage volume)/
baseline cartilage volume/time between MRI scans*100.
Secondary outcome measures
Progression of cartilage defects Cartilage defects will
be graded at tibial and femoral sites (0–4) from sagittal
images [37]. If multiple cartilage defects are present at one
site, the highest grade will be recorded. Our intra- and
inter-observer reliability for this method is 0.89–0.94 and
0.85–0.93, respectively [37]. The progression of cartilage
defects will be defined as any increase in cartilage defect
score in either tibial or femoral cartilage over 2 years.
Progression of BMLs BMLs will be defined as discrete
subchondral areas with increased signal intensity and ill-
defined margins on sagittal proton density images, and
graded at tibial and femoral sites (0–3). If multiple lesions
are present at one site, the highest grade will be recorded.
The intra- and inter-reader correlation coefficient for this
method has been reported to be 0.88–0.93 [13]. The pro-
gression of BMLs will be defined as any increase in their
grade in either tibial or femoral site over 2 years. The
maximum areal size will also be measured for each lesion.
The lesion with the largest size will be used if more than
one lesion is present at the same site. Our intra-observer
correlation coefficient for this method is 0.97 [38]. The
change in areal size of BMLs over 2 years will be assessed
since it is more sensitive to change, with positive results
seen over 6 months in a previous clinical trial [39].
Change in knee symptoms and function Knee pain,
stiffness and function will be assessed using a self-
administered validated questionnaire, WOMAC (the
Western Ontario and McMaster Universities Osteo-
arthritis Index) [40], at each study visit. It will be
used to describe the population, and change in symp-
toms and function measured by change in WOMAC
score will be a secondary outcome.
Other measurements
Anthropometry
Height (stadiometer), weight (electric scale) and body
mass index (height/weight2) will be measured at baseline
and 2 years.
Radiographic knee OA
A weight-bearing anteroposterior radiograph of the
study knee will be scored for osteophytes and joint space
narrowing on a four-point scale (0–3) using the Altman
atlas [33]. Our intra- and inter-observer reliability is 0.93
Table 3 Magnetic resonance imaging sequences and parameters at three study sites
Machine and coil T1 sagittal Proton density sagittal
Melbourne 3.0 T whole body MR unit (Achieva,
Philips Medical Systems), using a
commercial 16-channel transmit-
receive knee coil
T1-weighted fat suppressed 3D gradient recall
acquisition in the steady state; flip angle 15
degrees; repetition time 25.9 msec; echo time
9.2 msec; field of view 16 cm; 320 × 320 matrix;
one acquisition; partition thickness 0.5 mm
Proton density fat-saturated acquisition; flip
angle 90 degrees; repetition time 3,817 msec;
echo time 25 msec; field of view 16 cm; 720 ×
720 matrix; slice thickness 2.5 mm
Hobart 1.5 T whole-body MR unit (GE-Signa;
GE Healthcare, Buckinghamshire, UK)
using a dedicated 8-channel knee coil
T1-weighted fat-saturated 3D gradient-recalled
acquisition; flip angle 30 degrees; repetition
time 31 msec; echo time 6.8 msec; field of view
16 cm; 512 × 512 matrix; one excitation; slice
thickness 1.5 mm
Proton density fat-saturated 2D fast spin echo
sequence; flip angle 150 degrees; repetition
time 3,800 msec; echo time 39 msec; field of
view 16 cm; 512 × 512 matrix; 3 excitations;
slice thickness 3 mm
Adelaide 1.5 T whole-body MR unit (Aera,
Siemens) using a dedicated
15-channel transmit-receive
knee coil
T1-weighted fat-saturated 3D gradient-recalled
acquisition; flip angle 30 degrees, repetition
time 14.7 msec; echo time 6.74 msec; field of
view 16 cm; 448 × 448 matrix; one excitation;
slice thickness 1.5 mm
Proton density fat-saturated 2D fast spin echo
sequence; flip angle 180 degrees; repetition
time 3,200 msec; echo time 39 msec; field of
view 16 cm; 320 × 320 matrix; 1 excitation; slice
thickness 3 mm
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and 0.86 for osteophytes and 0.93 and 0.85 for joint
space narrowing, respectively [41].
Knee angle
The knee angle will be measured from weight-bearing
radiographs, as it affects cartilage volume change [42].
Our intra-observer correlation coefficient is 0.98 [42].
Tibial plateau bone area
The cross-sectional area of tibial plateau will be mea-
sured manually from the reformatted axial MR images.
The coefficient of variation of this method is 2.3–2.4 %
[34]. Cartilage volume will be adjusted for bone area to
account for joint size.
Meniscal tear and extrusion
The presence of meniscal tears and extent of meniscal
extrusion will be determined from sagittal images and
confirmed in coronal and axial images [43], as they
affect cartilage volume change [43]. The intra- and inter-
reader correlation coefficient has been reported to be
0.85–0.96 [43].
Physical activity
Physical activity will be measured using the International
Physical Activity Questionnaire (IPAQ) [44] short ver-
sion at baseline and 2 years.
Lower limb muscle strength
Lower limb muscle strength is expected to increase with
a decrease in pain, and therefore will be measured by dy-
namometry at months 0, 12 and 24. The muscles mea-
sured in this technique are mainly quadriceps and hip
flexors. The devices will be calibrated by suspending
known weights at regular intervals. Repeatability esti-
mates (Cronbach’s) were 0.91 [45].
Concomitant medication use
Concomitant medication use including glucosamine,
chondroitin, corticosteroids and non-steroidal anti-
inflammatory drugs will be allowed during the trial but
will be documented. There is no definitive data showing
that these treatments affect cartilage loss. The random-
isation process is the most effective method for ensuring
that two groups are as similar as possible with respect to
known confounders and unknown potential confounders
including treatments. We will adjust for medication use
in the analyses.
Cigarette smoking history
Cigarette smoking history will be assessed at baseline
and 2 years. As it affects cartilage loss and BMLs [46],
we will adjust for smoking status in the analyses.
Knee injury
Knee injury will be assessed at baseline and 2 years.
Prior knee injury is an exclusion criterion. Any signifi-
cant injury during the study will be documented, as it is
a risk factor for knee OA.
Safety assessment
Adverse events will be monitored throughout the study.
Standard safety and efficacy monitoring will be performed
through regular face-to-face visits and phone calls be-
tween visits. The participants are requested to report any
adverse events to the research staff spontaneously. Bio-
chemical testing (liver function tests, creatine kinase and
renal function tests) will be performed at 4 weeks, and at
6, 12 and 24 months. Details of the adverse event and its
relationship with study intervention will be recorded and
reported to the Ethics Committees.
Sample size calculation
Primary outcome
Based on our previous published data, the rate of tibial
cartilage volume loss in the control group was 3.0 +/− 3.0
per annum [47]. A 33 % reduction (that is, 1 %) in this rate
is clinically significant since this indicates a significant re-
duction in structural progression of cartilage damage. Our
previous work has shown that a 1 % reduction in the
annual rate of cartilage volume loss over 2 years decreased
the need for knee replacement surgery by 20 % over
a 3-year period based on the strong association between
the rate of cartilage volume loss and subsequent knee re-
placement [48]. With 140 participants in each arm, we will
have 80 % power to detect a 30 % reduction in the rate of
cartilage volume loss in the intervention group (2.0 %)
compared with the control group (3.0 %), with alpha error
0.05, two-sided significance. Given our previous experi-
ence in such studies, we expect a maximum dropout rate
of 20 % over 2 years. Therefore, a total of 350 participants
(175 in each arm of the study) will be recruited.
Secondary outcome
Based on our reported progression rate of 68 % for cartilage
defects [49] and 21 % [14] for BMLs over 2 years, with 140
participants per arm we will have 80 % power to detect a
17 % difference in the progression of cartilage defects and a
12 % difference in the progression of BMLs between the
intervention group and the control group. With 140 in each
arm, we will be able to detect a 30 % reduction in the
WOMAC pain subscale in the intervention group.
Statistical analysis
The primary analyses will be intention-to-treat analyses
of primary and secondary outcomes. Per protocol ana-
lyses (according to protocol adherence for patients who
have taken all the study medication and have had all the
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outcome measures) will be performed as the secondary
analyses. Intention-to-treat analysis will be carried out
by using multiple imputation [50], provided that patients
have had a baseline MRI. This analysis only requires
missing data to be missing at random to be valid. Differ-
ences within a treatment group between follow-up and
baseline measures will be assessed using a paired samples
t-test. The clinical efficacy measures, that is, changes in
pain and function, will also be analysed using the normal-
ised area under the curve for difference in scores from
baseline to month 24. Differences between treatment
groups will be assessed using independent samples t-tests,
ANCOVA (for continuous variables) or chi-squared tests
(for dichotomous variables). Multiple linear regression for
continuous endpoints or logistic regression for binary
endpoints could be carried out as supplementary analyses
for additional adjustment for imbalanced baseline factors.
Analyses of treatment efficacy will be done by censor-
ing participants at the time of any protocol deviation
and developing a model for the probability of deviation,
followed by weighted analyses using only the uncen-
sored participants where the weights are the inverse
probability of censoring. This produces estimates of
treatment effect as if there were full compliance with
the protocol in this trial and is far preferable to per
protocol analyses based on (unweighted) observed com-
pliance [51]. Pre-specified analyses to identify sub-
groups which may respond better to treatment will be
examined using stratified analyses; variables include
radiographic OA and co-pathology present on MRI.
Data integrity and management
All collected data are recorded using case report forms
which will be processed centrally at the Clinical Informat-
ics and Data Management Unit, Department of Epidemi-
ology and Preventive Medicine, Monash University. The
hard copies of the case report forms will be stored in a
locked area at each study site with secured and restricted
access. The electronic data will be stored in a password
protected database with secured and restricted access. All
data collected will be kept strictly confidential. Data trans-
fer will be encrypted with all data de-identified.
Withdrawal
If participants withdraw from the study before 2 years of
follow-up, the reason and date will be recorded. If the
participant withdraws after a minimum of 6 months of
treatment, he/she will be requested to have a second
knee MRI scan and complete the questionnaires.
Monitoring
The principal investigators will monitor the conduct and
progress of the project at each site. The trial coordinator
will visit each study site to make sure that all trial
procedures are compliant with the trial protocol. The
principal investigators and the research team will have
regular teleconferences to ensure efficient study execu-
tion and ongoing monitoring of the study progress, with
summary documents circulated after each meeting. An
independent Data and Safety Monitoring Board was con-
vened, consisting of a clinical rheumatologist, a clinical
cardiologist experienced in statin use, and a biostatisti-
cian, all with clinical trial experience. They will monitor
adverse events. They will meet annually or more often if
severe adverse events occur, and provide a written report
to the principal investigators.
Discussion
We proposed a multicentre, randomised, double-blind,
placebo-controlled trial to determine whether atorvastatin
has a disease modifying effect in symptomatic knee OA by
slowing the structural progression of knee OA and im-
proving knee symptoms. If atorvastatin is proven to be
effective, it will offer a novel therapeutic approach to redu-
cing the progression of knee OA.
Oral administration of statins is an established, safe and
well-tolerated treatment for the prevention of cardiovas-
cular events [23]. Extending the potential use of statins to
patients with knee OA is plausible. There is in vitro and in
vivo evidence that statins may reduce the progression of
OA via a number of pathways including their effects on
lipid metabolism and inflammation. Statins reduce the
levels of C-reactive protein and the production of inflam-
matory cytokines including IL-6 and IL-1β, most likely
through their inhibition of NF-kB activation in monocytes
or endothelial cells exposed to inflammatory stimuli [52].
Statins inhibit IL-1β induced production of matrix metal-
loproteinases (MMPs), and stimulate bone morphogenetic
protein 2, aggrecan, and synthesis of type II collagen and
cartilage matrix proteoglycan by chondrocytes [53],
which is protective against cartilage damage. Atorvastatin
inhibited IL-1beta-induced glycosaminoglycan release,
TNF-alpha, MMP-13, and superoxide anion formation,
protecting cartilage degradation following IL-1beta-stimu-
lated cartilage in an in vitro OA model [54]. In animal
models, statins reduce inflammatory cell infiltration
and matrix-degrading enzyme expression and inhibit
pro-inflammatory cytokines, thus reducing articular
cartilage degeneration and the severity and progression
of OA or arthritis [55–58]. In an anterior cruciate liga-
ment transaction induced rabbit OA model, intra-
articular statin injections reduced the gross morpho-
logical and histological changes in articular cartilage
[55]. In a mouse model resembling human lipoprotein
metabolism, atorvastatin significantly suppressed OA
development [59]. In a rabbit model of early experi-
mental OA, intra-articular application of atorvastatin
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showed chondroprotective effects both macroscopically
and histopathologically [60].
The previous human studies [25–30] (Table 1) are all
of an observational nature and thus susceptible to selec-
tion bias, information bias and confounding, and have
used insensitive tools to assess disease progression. Most
of these studies examined general OA without stratifying
by different joints, since emerging evidence suggests dif-
ferent pathogenic mechanisms of OA in knee and hip
joints, with the knee affected more by metabolic factors
than the hip [7]. A randomised controlled trial is re-
quired to determine whether statin use affects the struc-
tural progression of knee OA.
Although OA is a disease of the whole joint, progres-
sive articular cartilage loss is the hallmark of disease
progression. Radiographic joint space narrowing is the
gold standard to assess disease progression over time
and has been used as the primary endpoint to examine
the effect of disease modifying OA drugs in clinical trials.
However, radiographic joint space narrowing provides a
crude, insensitive method to assess disease progression
[36]. MRI allows non-invasive direct visualisation of all
joint components and direct measurement of articular
cartilage, representing a sensitive method to assess OA
progression. Cartilage volume has been validated by com-
parison with anatomical specimens [61]. It is a clinically
useful measure which is inversely correlated with radio-
logical grade of OA [41]. Cartilage volume loss is clinically
significant, as it predicts important patient outcomes of
pain [62] and risk of joint replacement [48]. Cartilage
defects have been validated against surgically confirmed
cartilage lesions and arthroscopy [63]. They are associated
with knee pain [12], predict cartilage loss independent of
cartilage volume [64], and predict joint replacement [49],
thus providing a further assessment of cartilage health.
Being the most common subchondral bone abnormality
described in OA, BMLs are associated with knee pain
[65], predict disease progression [66], cartilage volume
loss [13] and joint replacement [14]. Thus, these MRI-
assessed knee structural changes have been chosen as the
primary and secondary outcome measures in this study.
In summary, knee OA is the most common form of
chronic joint disorder but has no proven pharmaco-
logical treatment that reduces structural disease progres-
sion. There is evidence that both inflammation and lipid
metabolism contribute to the progression of OA. The
anti-inflammatory and lipid lowering effects of stains
make this class of drug a potential treatment approach
to slowing the progression of OA. This randomised con-
trolled trial will provide high-quality evidence to address
whether atorvastatin has a novel disease modifying effect
in OA by delaying the structural and symptomatic pro-
gression of knee OA. If demonstrated to be effective,
atorvastatin could be used as a novel disease modifying
agent to delay the onset of end-stage OA and the need
for primary joint replacement for OA and possibly revi-
sion surgery. This has major public health importance,
as it would produce substantial cost savings by delaying
and possibly reducing the need for joint replacement
surgery, and provide marked improvements in quality of
life for people with knee OA.
Trial status
Upon submission, the OAKS study is in the process of
patient recruitment.
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